SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Tuesday reported a loss of $65.2 million in its third quarter.
On a per-share basis, the San Diego-based company said it had a loss of 53 cents.
The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 63 cents per share.
The drugmaker posted revenue of $35.6 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $31.5 million.
Acadia shares have climbed 12 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $32.42, a climb of 41 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACAD at https://www.zacks.com/ap/ACAD